Good afternoon. My name is Chantelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme 3rd Quarter 2022 Financial and Operating Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's month, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one your telephone keypad. If you would like to withdraw your question, please press star one again. Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead. Thank you, operator. Good afternoon, and welcome to our 3rd quarter 2022 financial and operating results conference call. In addition to the press release issued today after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the investor relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Nicole Labrosse, our Chief Financial Officer, who will review our financial results for the 3rd quarter ended September 30th, 2022. On today's call, we will be making forward-looking statements. I refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. The non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Helen Torley. Thank you, Tram, and good afternoon, everyone. I am pleased that our 3rd quarter results continue to reflect both strong financial and operational performance across the business. I'll begin on slide three with what is excellent news. I'm delighted to announce that we achieved an all-time high quarterly royalty revenue of almost $100 million in the 3rd quarter. This represents strong growth of 70% over prior year 3rd quarter and continues to demonstrate the strength of our enhanced business. Total quarterly revenue was $209 million, also a record, with strong growth of 80% over same period prior year. Our total revenue growth results from our diversified portfolio, which includes growing ENHANZE revenues resulting from royalty and milestone revenue, incremental product sales, and incremental royalties resulting from the sales of Teva's EpiPen, which utilizes our small volume auto-injector, and also from sales of XYOSTED, our specialty commercial testosterone replacement therapy. We're pleased with this strong momentum and the growing diversification of our revenues. Over the past several years, and supported by the acquisition of Antares in May, we have built a leading subcutaneous drug delivery platform company with a specialty business that has compelling growth opportunities, diversified revenue streams, and extended revenue durability. We look forward to leveraging our ENHANZE capabilities to support current and new partners utilizing ENHANZE, our auto-injectors, and our auto-injectors plus ENHANZE, with the goals of increasing their product's competitiveness and reducing the burden of treatment for patients. With a dedicated focus on operational excellence for the combined business, our vision remains to deliver disruptive solutions that significantly improve patient experiences and positively influence outcomes. Based on strong year-to-date results, our communication with partners, and planned expenditures for the year, we're also reiterating our guidance for 2022. As previously disclosed, we expect total revenues of $655 million-$685 million for the full year 2022. We expect revenue from royalties to increase greater than 70% year-over-year to approximately $350 million-$360 million. I'll now move to slide four and provide more detail on our royalty revenue performance in the quarter. We're very pleased with the continued robust growth of this high-margin recurring revenue stream. In the 3rd quarter, total royalty revenue was $99.6 million, representing 70% growth over the 3rd quarter of 2021 and 17% sequential growth. These results include our enhanced royalties and the auto-injector device royalty stream. Our Wave Two products, DARZALEX Subcutaneous and Phesgo, continue to drive our overall strong royalty revenue growth. The robust and rapid adoption of DARZALEX sub-Q in U.S. and Europe demonstrate that adoption shows no real barriers in both geographies. Phesgo, growing rapidly in Europe, demonstrates the acceptance of the fifth sub-Q product with ENHANZE. ENHANZE sub-Q products have clearly shown that they were adopted by payers, physicians, and patients worldwide. This bodes well for our Wave Three, four, and five product launches. Moving now to slide five, which focuses on DARZALEX. DARZALEX Faspro, which is the subcutaneous version of DARZALEX in the U.S., continued its remarkable growth story in Q3, achieving 85% share of total sales of DARZALEX. At the same time, total DARZALEX sales also continued to demonstrate strong growth. On their 3rd quarter update call, Janssen's parent, Johnson & Johnson, reported worldwide sales of DARZALEX, including both the IV and subcutaneous forms, $2 billion, an increase of more than 38% year-over-year on an operational basis. The increase in DARZALEX sales was driven by share gains in all regions, continued strong market growth, and continued uptake of Faspro, the subcutaneous formulation with ENHANZE. Also illustrated in the slide is an update on analyst consensus for DARZALEX total revenue. It is now projected to achieve $12 billion in sales in 2025, with strong continued growth driven by increased penetration into the earlier lines of treatment. I'll move now to Phesgo. On their 3rd quarter call, Roche reported strong sales of Phesgo, a combination of Perjeta and Herceptin for subcutaneous injection for patients with early and metastatic HER2-positive breast cancer. Sales continued to show a strong uptake in Europe and the U.S.. Phesgo revenue was CHF 526 million for the 1st nine months of 2022, an increase of 150% year-over-year. Phesgo's faster subcutaneous administration in just minutes compared to hours with standard intravenous administration has contributed to lower healthcare costs and use of resources and is rapidly becoming the leader in many markets. On the 3rd quarter call, Roche reported 30% conversion in the early launch countries and stated that they expect Kesimpta to be an important medicine for years to come. Chugai, a member of the Roche group, also recently filed for regulatory approval in Japan, which could represent another opportunity for continued Kesimpta growth. Moving now to slide six. Our next waves of potential launches are illustrated here. Focusing on Wave Three, these products represent the next set of royalty revenue opportunities, with potential launches projected between 2023 and 2025. The Wave Three products are subcutaneous efgartigimod, atezolizumab, nivolumab, and ocrelizumab. Our future growth trajectory is also supported by potential launches of our Wave Four products in the 2025 to 2027 timeframe. Wave Four is comprised of 11 partner products, 10 of nine which are in ongoing phase I clinical testing or have completed phase I testing. I'm pleased to note that one of the phase IV products, Janssen's amivantamab, recently advanced into phase III clinical testing. Slide seven highlights the recent advancements in Wave Three products during the 3rd quarter. In September, argenx announced the submission of a Biologics License Application, or a BLA, to the FDA for the ENHANZE-enabled subcutaneous efgartigimod for the treatment of generalized myasthenia gravis. Efgartigimod subcutaneous is on track to be the 1st of Wave Three potential partner launches, with potential U.S. approval anticipated in 2023. Efgartigimod as an intravenous drug, which has the brand name Vyvgart, is argenx's flagship product, and it is being developed as an IV and a sub-Q for multiple autoimmune disease indications. Analysts project multi-billion dollar revenue potential for efgartigimod. As the intravenous version, efgartigimod has been approved and launched in the U.S., Japan, and as of September, also in Germany, for the treatment of adult patients with generalized myasthenia gravis. On their recent 3rd quarter call, argenx noted strong physician and patient demand for Vyvgart and reported total quarterly net product revenues of $131 million, with 2,000 patients on treatment. In addition to the already submitted BLA application for myasthenia gravis, we are excited to be partnering with argenx to evaluate efgartigimod subcutaneous with ENHANZE in five additional autoimmune indications and expect multiple data readouts projected in 2023, including data in idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and also pemphigus. I'll move now to Roche. Roche is our most experienced partner with ENHANZE, and we're delighted that two of our four Wave Three opportunities are with Roche. These are Tecentriq subcutaneous and Ocrevus subcutaneous. Recently, Roche reported that their IV Tecentriq revenues increased 10% to CHF 2.7 billion for the 1st nine months of the year, demonstrating continued strength for this important product. We're looking forward to U.S. and European regulatory submissions for Roche's Tecentriq with ENHANZE. Supporting this, in August, Roche announced that its phase III study evaluating the subcutaneous formulation of Tecentriq, or atezolizumab, with ENHANZE in patients with advanced non-small cell lung cancer met its co-primary endpoint. The study showed non-inferior levels of Tecentriq in the blood when injected subcutaneously compared to intravenous infusion in immunotherapy-naive patients with advanced or metastatic non-small cell lung cancer for whom prior platinum therapy had failed. The safety profile of the subcutaneous formulation with ENHANZE was also consistent with IV Tecentriq. Subcutaneous Tecentriq, upon approval, has the potential to reduce the treatment time for Tecentriq to 3-8 minutes as a subcutaneous delivery, down from 30-60 minutes for IV treatment. Moving to Ocrevus, Roche is experiencing strong recruitment for the phase III trial of subcutaneous ocrelizumab, or Ocrevus, with ENHANZE and expects topline data for this trial in 2023. Ocrevus as an intravenous treatment, according to Roche's remarks on their 3rd quarter update call, is currently the number one treatment in the U.S. and EU5 for multiple sclerosis, both in terms of total share and new-to-brand share. Total revenues for the 1st nine months were CHF 4.4 billion. With more than 250,000 patients treated globally, Roche also commented that Ocrevus is experiencing higher persistence than other multiple sclerosis drugs. Completing Wave Three products, BMS continues to progress with their phase III study of subcutaneous nivolumab, or Opdivo, utilizing ENHANZE in patients with renal cell cancer. BMS also recently initiated a 2nd phase III study of nivolumab subcutaneous with ENHANZE in patients with melanoma. In addition, as you may be aware, the fixed-dose combination of IV nivolumab and relatlimab, called Opdualag, is now approved in the United States and Europe for the treatment of certain patients with advanced melanoma. We look forward to the results of the phase I study of subcutaneous administration of nivolumab and relatlimab with ENHANZE and an update on future development plans by Bristol Myers Squibb. The cumulative revenue opportunity for the Wave Three products is substantial, with analyst projections for IV and subcutaneous versions increasing from $19 billion in 2022 to $27 billion in 2025. Halozyme's royalties from this large commercial opportunity will depend upon the timing of approval of the subcutaneous version within the projected 2023-2025 time window and the speed and peak of conversion to subcutaneous. I'll move now to our wave four product and slide eight. Our goal is to continue to expand the number of products in development and to advance products to later stages of development towards regulatory approval and launch. Our goal for 2022 is to support initiation of at least 10 new studies, including achieving more than six new phase II or phase III trial starts for existing ENHANZE partner programs, and to advance two new products to enter the clinic this year. I'm pleased to report that we are on track to meet this goal. Supporting this progress, in September, Janssen initiated a phase III study of lazertinib plus amivantamab with ENHANZE in patients with epidermal growth factor receptor mutated, advanced or metastatic non-small cell lung cancer. Also in the 3rd quarter, we recognized $48 million in collaboration revenue, the majority related to Bristol Myers Squibb and Roche progressing towards development events. We are pleased with the continued progress by our partners. With four products Wave Three with the potential to launch beginning next year in 2023, and a robust set of 11 Wave Four launch opportunities, we have multiple potential growth drivers of robust future royalty revenue growth. Moving to slide nine, our acquisition of Antares further strengthened our leadership in drug delivery. In the 3rd quarter, we had multiple productive discussions with current partners as well as potential partners on ENHANZE on our current small-volume auto-injectors and also the opportunity to collaborate on a high-volume auto-injector, enable injections of up to 10 milliliters with ENHANZE. By combining an innovative auto-injector platform with ENHANZE, we see a unique opportunity for patient-friendly, high-volume subcutaneous treatment delivery that can be utilized across a spectrum of disease areas for both small molecule drugs and for biologics. We currently are conducting feasibility study and expect to have a working prototype of our high volume auto-injector by year-end that can then be incorporated into clinical testing. Our goal remains to expand the number of companies licensing both our ENHANZE and our auto-injector technologies. Let me now turn your attention to our specialty business, which includes XYOSTED, TLANDO, and Luxturna. We remain focused on accelerating growth of XYOSTED, our weekly, virtually painless subcutaneous testosterone replacement treatment, which is delivered by auto-injector. Every month, we are achieving new weekly high average prescription performance and believe there is still a significant opportunity to grow our share of the total testosterone replacement therapy market. To dimensionalize this, each market share point represents more than $20 million in incremental sales. With a growth rate that outpaces the overall testosterone replacement therapy market, our plan is to continue to switch patients from intramuscular injections, which can be associated with pain and can require physician or healthcare practitioner administration. Intramuscular testosterone represents about 75% of the approximately 8.5 million annual testosterone replacement therapy prescription market volume today. We also recently launched TLANDO, our twice-a-day oral testosterone replacement treatment. Our access team remains focused on gaining and expanding coverage by payers for TLANDO. We expect that our negotiations with the pharmacy benefit managers will be similar in duration to other commercial launches, which can take six-12 months until access is established. I'll move to slide 10 now. Before I hand the call over to Nicole, let me reiterate our commitment to our strategic growth and capital allocation priorities. In summary, we expect to enhance our growth by investing in the growth of our drug delivery business and our commercial business. We continue to return capital to shareholders with our share buyback, and we will also continue to seek opportunities for external growth, noting that our current focus remains on driving operational excellence of the Antares acquisition. I'll now turn the call over to Nicole to discuss our 3rd quarter financial results. Nicole? Thank you, Helen. I'll begin on slide 11. We are excited to report our 3rd quarter, reflecting a full quarter contribution from the Antares acquisition, which was accretive to Q3 revenue and non-GAAP EPS. We continue to project that the Antares acquisition will be accretive to revenue and non-GAAP EPS for the full year of 2022. Through this acquisition, we added a new platform technology and commercial products that adds to revenue and can extend the durability of our revenue while being accretive in the 1st seven months. Total revenue for the 3rd quarter was $209 million, compared to $115.8 million in the prior year period. The year-over-year increase of 80% was primarily driven by an increase in royalty revenue and the addition of product sales as a result of the Antares acquisition, as well as an increase in revenues under collaborative agreements due to milestones recognized from BMS and Roche. Royalty revenue for the 3rd quarter was $99.6 million, an increase of 70% compared to $58.6 million in the prior year period. The year-over-year increase was primarily driven by continued strength in uptake from Janssen's subcutaneous DARZALEX utilizing ENHANZE. Cost of sales for the 3rd quarter were $47.3 million compared to $18.6 million in the prior year period. The year-over-year increase was primarily driven by an increase in product sales as a result of the Antares acquisition, including adjustments to reflect the amortization of the inventory step-up at fair value. Research and development expenses for the 3rd quarter were $16.7 million, compared to $8.5 million in the prior year period. Selling, general, and administrative expenses for the 3rd quarter were $34.5 million, compared to $13.2 million in the prior year period. The year-over-year increase in R&D and SG&A expenses was primarily due to the Antares acquisition and an increase in compensation expense related to the combined larger workforce. Operating income was $83.3 million, compared to $75.6 million in the prior year period. Q3 2022 includes the impact of amortization of intangibles of $27.2 million related to the Antares acquisition. On a GAAP basis, diluted earnings per share was $0.44 compared to $1.48 in the prior year period. On a non-GAAP basis, diluted earnings per share was $0.74 compared to $0.55 in the prior year period. When comparing to the prior year, it's important to note that 2022 is our 1st year of recording income tax expense, which impacted current period GAAP and non-GAAP diluted EPS by $0.09 per share. In August, we completed the sale of $720 million convertible note. We used the proceeds to refinance our floating rate secured bank debt and replaced it with unsecured 1% coupon note. We also repurchased a majority of the remaining 24 notes that were significantly in the money. We continue to have access to pro rata bank debt through our revolving credit facility. In August, we increased the size of the revolving credit facility from $350 million to $575 million. Our balance sheet remains threetrong, with 3.3x net debt to EBITDA ratio as of September 30, 2022, which we expect to reduce to less than 3.3x by the end of the year. We continue to execute on our previously announced three year, $750 million share repurchase program, inclusive of the $150 million accelerated share repurchase initiated in December 2021, which concluded in June. In the 3rd quarter, we repurchased 2.1 million shares for $90 million. We also entered into an ASR to repurchase $110 million and took initial delivery of two million shares for a total of $350 million repurchased under the plan to date. With our 2022 repurchases, our share buyback programs have resulted in the repurchase of 30.3 million shares since 2019, positively impacting Q3 2022 non-GAAP EPS by $0.14. Moving now to slide 12. Based on the contributions of the Antares transaction and strong year-to-date results, as well as the latest information from our collaboration partners and planned expenditures for the year, we are reiterating our guidance for 2022. As disclosed in our 2nd quarter earnings call, we expect total revenues of $655 million-$685 million for the full year 2022. This includes the projected revenue contributions from the Antares business, which is expected to contribute $115 million-$125 million to the full year guidance. We expect revenue from royalties to increase by more than 70% over revenue from royalties in 2021 to approximately $350 million-$360 million. Due to an acceleration in some Wave Three and Wave Four milestone revenue that we had expected in Q4 and have now recognized in Q3, we have achieved the vast majority of milestones expected in 2022. Collaboration revenues for 2022 are expected to be lower than the levels we achieved in 2021 based on the latest updates for expected timing of partner milestone-bearing events. Product sales from 2022 are expected to increase from 2021 due to the contribution of sales from the Antares acquisition. We expect operating income of $240 million-$265 million, which includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition. Adjusting to these costs, we expect adjusted operating income of $365 million-$390 million. We expect GAAP diluted earnings per share of $1.20-$1.35. Adjusting for acquisition-related costs and other adjustments, we expect non-GAAP diluted earnings per share to be $2.10-$2.25, representing an increase of 5%-12% over 2021 non-GAAP diluted earnings per share. With that, I'll now turn the call back to Helen. Thank you, Nicole. As you heard today, we are continuing to build on the momentum for ENHANZE and our auto-injector and commercial business. We achieved a new all-time high for royalty revenue of nearly $100 million in the quarter. We achieved a record $209 million in total revenue in the quarter. Our acquisition is being validated by the progress being made in developing a differentiated large volume auto-injector plus ENHANZE, which is projected to expand our subcutaneous offering to current and new partners and to extend the durability of our royalty revenue. You'll hear more of this in 2023. The acquisition also accomplished our goal of diversifying our revenues with the product sales from our small volume auto-injector agreement and XYOSTED contributing to our 3rd quarter revenues. I'll close by thanking our Halozyme team and our partners and collaborators for the strong progress made during the quarter. Thank you all for joining us today. With that, we'd be delighted to take your questions. Operator, would you please open the call for questions? At this time, I would like to remind everyone, in order to ask a question, please press star one. Our 1st question comes from Michael DiFiore with Evercore ISI. Your line is open. Hi, guys. Thanks so much for taking my question, and congrats on the quarter. Just three from me. Number one, on the last call, you mentioned that Halo was going to reach out to potential partners to promote your new suite of auto-injector offerings. Any color on the progress made or outcomes achieved on this front? My 2nd question is just thinking through the subcutaneous Ocrevus commercial opportunity. You know, granted that Kesimpta from Novartis is administered sub-Q once monthly doing about half the sales and volume of IV Ocrevus. My question is, should we expect a similar trajectory for subcutaneous Ocrevus, or would sub-Q Ocrevus' potential less frequent dosing really matter here and boost sales in that regard? My last quick housekeeping question is that I've been getting a lot of questions from investors on the potential impact to Halozyme, assuming that Makena will be pulled from the market. Thank you. Thanks, Mike. I'll begin with the update on the reach out to partners and potential new partners actually on the auto-injectors and the auto-injectors plus ENHANZE. I can say that we are engaged in multiple calls, and there is a lot of interest, particularly on the higher volume approach, as there is no way to deliver volumes of 5 mL and above today, using an auto-injector. I can just say the conversations are going well. There's interest, there's good recognition. This is a differentiated approach. Stay tuned as we continue to work on our prototype, and hopefully next year are in a position to move forward into more in vivo testing of the effectiveness of our new auto-injector. Moving to subcutaneous Ocrevus, I think, if we think about the opportunity here, Michael, I mentioned on the call that IV Ocrevus, globally is now a $4.4 billion brand. Patients who are receiving that go in and get an infusion, which, although it's sped up over the years, if you actually look at some slides Roche put together, the patients are required to be in the infusion suite for many hours. I think the way Roche has positioned this is as an option for those patients, perhaps because they don't want to spend time in the infusion suite or the infusion suites are busy, for those patients instead to receive the subcutaneous version of the drug. Just going down to minutes instead of these hours I think is going to be very meaningful for patients with MS, which obviously is a lifelong condition. We're very excited about that. If you listen to the Roche calls, they certainly are saying some very positive things about it, as well. On Makena, obviously we are aware that there was a negative note. There's been no final decision with regard to that. What I can say about Makena is, it's a very small contributor to the Halozyme revenues. It will not have any impact on our performance in 2022 or 2023, whatever the decision is. Got it. Very helpful. Thanks so much. Our next question comes from Jessica Fye with JP Morgan. Your line is open. Hey, guys. Good evening. Thanks for taking my questions. On the large volume auto-injector, can you help us understand the timelines or next steps that need to happen between achieving a working prototype and bringing the product to market? With DARZALEX Faspro US conversion now at 85%, how do you think about the realistic peak conversion from here and the time frame it could take to get there? Lastly, operating expenses. Now that we've got a full quarter with Antares in the mix, how should we think about the run rate for OpEx as we look ahead to 2023? Thank you. I'll start with the 1st, and then I'll turn it over to Nicole for OpEx. The large volume auto-injector, working prototype at the end of this year. As we talk with different companies, each of them will have a slightly different need as it relates to the auto-injector. Our goal is to start working with one or more companies to then move forward into getting into the clinic and testing the auto-injector, having further developed it. There'll be a period of further development, Jess, just to get it right for what that partner needs, and then move into clinical development. If this is a product that a partner is already sub-Q and they want to move it into an auto-injector, perhaps today they have a prefilled syringe and they want an auto-injector, that we estimate will be a pretty straightforward and rapid path because we'll just be seeking to demonstrate non-inferiority. If this was an intravenous drug that the partner wants to move to sub-Q with auto-injector, think of that being more like the pathway for ENHANZE, phase one study to find the dose, and then a phase three study to demonstrate non-inferiority. Just based on conversations we're having, we believe that both those pathways are possible, certainly with the interest being expressed by companies both, sub-Q to auto-injector and IV to sub-Q with auto-injector, conversion. 2nd question, with regard to DARZALEX 85%, you know, it is hard to estimate just how high it will go. But when you think about the value proposition here, where our patients have the option to get 3- to five5-minute sub-Q injection as opposed to an often 4+ hour IV infusion, we certainly think there is a lot of continued growth possible in here, with only a few patients, we think, electing to remain on the IV, perhaps because they like the community of the infusion suite. We do think over time we're just going to continue to see the conversion rate increasing and can't put an estimate on it, but conversion will continue to grow beyond the 85% in the US and the estimated 80% outside the US. I'll just also say we're excited by the growth of the overall brand. I mentioned on the call that in the 3rd quarter revenue grew 38% on an operational basis to $2 billion. That really is remarkable. It's in part because of this increased penetration into the front line that the sub-Q version, based on Janssen's comments, is enabling, which is a large population. Importantly, these patients stay on therapy. The growth is going to come from share penetration, but also by the fact the overall brand is growing. We see future growth, absolutely. I'll turn it to Nicole for the operating expenses. Yeah. Thanks, Jessica Fye. On the operating expense side, what I can say is you will have seen that Q3 is a bit more representative of our go-forward run rate now being the 1st full quarter with the combined entities. Looking at 2022, thinking about next quarter, it is a good representation. One thing that just comes to mind quarter-over-quarter, looking into next quarter is just a little bit of uptick as we filled some headcount vacancies this quarter. So we'll see the full impact of that in next quarter. With regards to 2023, more to come there. We have not provided our guidance yet for 2023, and we plan to do so early next year. Our next question comes from David Risinger with SVB Securities. Your line is open. Thanks very much. I have a couple questions, please. I guess 1st I wanted to ask about slide eight, if that's okay. I was hoping that you could just explain that slide in some detail so that I understand what you're trying to convey there and where things currently stand in early November. David, just to confirm, slide eight, just to make sure our numbering is working, you're saying this is the wave four product stem status? The title of slide eight i s, "Expected in 2022, at least 2 new product candidates to enter clinic and over six new phase II/3 starts." I was just wondering, in light of that heading, which of those have been disclosed to date and completed to date and what needs to happen over the next, I don't know, less than 60 days? Oh, all right. Perfect. We can say that, in terms of the new phase II/3 starts, we're very pleased on this call to have noted that amivantamab has moved into phase III clinical testing, as you see, listed there. We can also say that at the beginning of the year, from a phase I perspective, on this slide, we saw N6LS, as well as the SUGE-I drug, which are at the bottom of the slide, move into phase I clinical testing. Maybe all the slides actually are not in this deck, so I do apologize for that. The other studies actually are in Wave Three launches. Thank you for catching that, David. When we post this, we actually have both slides there. I don't actually know why we're missing our Wave Three. That will just give you a sense of the products that have moved forward, and we'll need to make sure that we have this full set in the deck that we will provide. Okay. Thank you. Just a couple of other questions. Congrats on the imatinib advance into phase III. Just so that I understand your disclosure, how was that Janssen program previously disclosed by the company? Was it named- Yeah. was it just, an unidentified J&J program? I just don't know how you handled that disclosure previously. We work with our partners on their preference for how things are disclosed. In our SEC filings, like, as an example, our 10-K and 10-Q, it was disclosed as amivantamab. In our presentations for earnings calls, it was undisclosed because, again, we work with our partners and their preference, but it's been disclosed since the beginning in our SEC filing documents. Okay, that's very helpful. What should we expect the company's normalized non-GAAP tax rate to be in 2023 and beyond? David, we haven't provided that level of guidance and out to 2023. What I can say about 2022, and you'll have seen in our results for this quarter, our effective tax rate is about 19%. We did have the ability to reduce that a little bit this quarter, looking at the combined entities and specifically our state tax obligations. That's the expectation for this year and we're looking forward to sharing more on next year at a later date. Okay. Thank you very much. Congrats on the progress. Thank you, David. Thank you. Thank you. Our next question comes from Jason Butler with JMP. Your line is open. Hi. Thanks for taking the questions. I just had two. Helen, you spoke about the fact that there's interest in both the auto-injector as well as combining the auto-injector with ENHANZE. Is there, you know, on balance, to what extent is the interest in one bucket versus the other? And then secondly, just on the specialty business, can you talk about, you know, commercial integration and how you think about getting the specialty business to break even? Do you think you can do it with the current proprietary product portfolio alone or are there, you know, strategic things you're thinking about, including bringing in additional products into that business? Thanks. All right. Yeah. I would say that on balance there is more interest and I think excitement with regard to ENHANZE with the large volume auto-injector, frankly, because that's not something that is available in any format for partners on the marketplace today. Small volume auto-injectors, there are other versions. We do not think they're as differentiated or as customizable as ours. But where the novelty and innovation is coming is the ability to deliver up to 10 mL rapidly via auto-injector, which is what we are seeking to develop with high volume, Jason. So definitely the high volume with ENHANZE getting the greatest interest. And with regard to specialty, I mean, I commented on the call that the testosterone market is a growing market and a large market. Every 1% share we can gain with our products is about $20 million. There absolutely is a path, and it's our goal to be able to break even on this just simply with the products that we have in the portfolio today. Definitely a lot of opportunity and liking the recent growth we're seeing in our Darzalex. Great. Thanks for taking the question. Our next question comes from Corinne Jenkins with Goldman Sachs. Your line is open. Yeah. Good afternoon, everyone. Maybe one for me. As you think about indications that may be most appropriate for an auto-injector delivery method versus maybe indications that aren't necessarily as appropriate for an auto-injector delivery method for whatever reason, how does that compare to kind of the existing partner portfolio that you have? Yeah. I think, Corinne, as I think about that, I think if it's an indication where the patient is more likely to be administering it at home, that is a more obvious place for an auto-injector, just off the top of my head. That can be both small molecules and biologics, where if the product label does not suggest there's any need for physician supervision. Perhaps areas more like autoimmune disease, neurology, psychiatry, those types of areas. However, I would also say there is nothing to preclude auto-injectors being delivered by healthcare professionals in an office setting as well, because that really is a nice, quick, convenient way to deliver drug as well. Yeah, I think hopefully that is helpful. Just to like say anything can be delivered via auto-injector, we believe. There, I would say that, think about it both as an at-home delivery, which is probably areas outside oncology. Even in an in-office setting, perhaps areas like oncology, it might be more suitable there. Okay. Helpful. Can you just frame for us some of the potential drivers for subcutaneous adoption in the context of what's a pretty competitive PD-1, PD-L1 landscape? And, just any context that you can provide there would be helpful. Yeah, we certainly are excited about the progress we're seeing with both Tecentriq making progress and Opdivo making progress to have subcu versions. You know, the way I look at it, we start 1st with what the company's strategy is. Both Roche and Bristol have talked about the importance for patients in reducing the treatment burden, which the shorter subcu would do. The opportunity to combine drugs, BMS is doing that obviously with Opdivo and relatlimab, further reducing the burden and importantly, competitive differentiation. It is very clear that everybody's moving towards more convenient delivery of immune checkpoint inhibitors and obviously our subcu is enabling that. I think the next comes into the patient benefit. Is there any benefit that even goes beyond convenience like we've seen with some of our other products? We believe that the positioning of the subcu products with ENHANZE is going to place both Bristol and Roche in a very nice position against the competition in PD-1, PD-L1, and importantly, really do a lot to support patients by reducing the burden they're going through as they're receiving their cancer therapy. Okay, thanks. Just a quick point of clarification. When you have the combinations like nivolumab and relatlimab, are those in a single co-formulation with ENHANZE or are they two separate auto-injectors? That one is just like Phesgo, it's the two drugs with ENHANZE in a single injection. Great. Thank you. Again, if you would like to ask a question, please press star one. We have reached the end of our question and answer session. I'll now turn the call back over to Helen for closing remarks. Thank you very much, everybody. As you've heard, we're very excited with the continued momentum of ENHANZE, also our auto-injector progress as well as our commercial business. We look forward to providing updates next quarter of the continued success and growth of Halozyme. Thank you. This concludes today's conference call. You may now disconnect.